Literature DB >> 26619354

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.

Peter B Bach1, Steven D Pearson2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26619354     DOI： 10.1001/jama.2015.16843

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  19 in total

1.  Analysis of Value-Based Costs of Undesignated School Stock Epinephrine Policies for Peanut Anaphylaxis.

Authors:  Marcus S Shaker; Matthew J Greenhawt
Journal:  JAMA Pediatr       Date:  2019-02-01       Impact factor: 16.193

Review 2.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

3.  Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.

Authors:  Charles W Given; Barbara A Given; Cathy J Bradley; John C Krauss; Alla Sikorskii; Eric Vachon
Journal:  J Oncol Pract       Date:  2016-10-31       Impact factor: 3.840

4.  ENGAGING LEARNERS TO ACHIEVE ESCAPE VELOCITY IN TRANSFORMATIONAL EDUCATION AND PRACTICE.

Authors:  C C Matson; M B Stephens; A K Davis; A Tallia; A Wilke
Journal:  Ann Fam Med       Date:  2016-03       Impact factor: 5.166

Review 5.  Considerations in the development of generic disease therapies for multiple sclerosis.

Authors:  Le H Hua; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2016-08

Review 6.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

Review 7.  Review of Current Policy Strategies to Reduce US Cancer Drug Costs.

Authors:  Angela K Green; Jennifer A Ohn; Peter B Bach
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 8.  The rising cost of diabetes care in the USA.

Authors:  Patricia Peter; Kasia Lipska
Journal:  Lancet Diabetes Endocrinol       Date:  2016-05-04       Impact factor: 32.069

9.  Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.

Authors:  Eric L Ross; Djøra I Soeteman
Journal:  Psychiatr Serv       Date:  2020-07-07       Impact factor: 3.084

10.  Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.

Authors:  Eric D Shah; Sameer D Saini; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-01       Impact factor: 11.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.